University of Colorado School of Medicine: Division of Rheumatology
Welcome,         Profile    Billing    Logout  
 7 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Moreland, Larry W
NCT06201416: Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis

Recruiting
1
24
US
SBT777101
Sonoma Biotherapeutics, Inc.
Rheumatoid Arthritis
03/26
03/26
Wagner, Elizabeth J
GLEAM, NCT06294236: Study Evaluating SC291 in Subjects with Severe R/r B-cell Mediated Autoimmune Diseases

Recruiting
1
36
US
SC291, Cyclophosphamide, Fludarabine
Sana Biotechnology
Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
12/27
03/28
Podoll, Amber
EAGLE, NCT03749447 / 2018-003253-24: An Extended Access Program for Bardoxolone Methyl in Patients With CKD

Terminated
3
270
Europe, Japan, US, RoW
Bardoxolone methyl, RTA 402
Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc.
Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney
08/23
08/23
FALCON, NCT03918447 / 2018-004651-20: A Trial of Bardoxolone Methyl in Patients With ADPKD -

Terminated
3
667
Europe, Japan, US, RoW
Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule
Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC
Autosomal Dominant Polycystic Kidney, ADPKD
08/23
08/23
GLEAM, NCT06294236: Study Evaluating SC291 in Subjects with Severe R/r B-cell Mediated Autoimmune Diseases

Recruiting
1
36
US
SC291, Cyclophosphamide, Fludarabine
Sana Biotechnology
Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
12/27
03/28
Clauw, Andrew
NCT06201416: Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis

Recruiting
1
24
US
SBT777101
Sonoma Biotherapeutics, Inc.
Rheumatoid Arthritis
03/26
03/26
Sahakian, Lori
SIRIUS-LN, NCT05126277 / 2020-005830-14: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Recruiting
3
420
Europe, Canada, US, RoW
ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Lupus Nephritis
03/27
07/30
NCT06153095: A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Recruiting
1/2
30
US, RoW
IMPT-514
ImmPACT Bio
Systemic Lupus Erythematosus, Lupus Nephritis
02/27
02/27

Download Options